Park Medi World Q1: consolidated PAT ₹88.6 Cr up 35% YoY as new hospitals scale
PAT +35.24% YoY · revenue +19.27% · margins expanding
₹475.71 Cr
+19.27% YoY
₹88.59 Cr
+35.24% YoY
18.33%
₹2.05
Park Medi World's first standalone-listed quarter (IPO Dec-2025) shows the consolidated engine firing on capacity additions: revenue from operations of ₹475.7 Cr grew 19.3% YoY (a softer +3.3% QoQ), and consolidated PAT of ₹88.6 Cr rose 35.2% YoY, with the parent's share at ₹82.5 Cr (EPS ₹2.05 vs ₹1.70 a year ago). Crucially, pre-tax profit of ₹105.1 Cr was up 28.3% YoY, so the earnings growth is operational rather than accounting — but the eye-catching +15% QoQ PAT is largely a tax effect: the effective tax rate fell to 15.7% (a ₹9.3 Cr deferred-tax benefit) from 25.7% in Q4, while PBT was essentially flat sequentially. The standalone entity is just a small holding company (revenue ₹33.5 Cr, PAT ₹1.1 Cr); the consolidated figures are the real business.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
On margins, net profit margin expanded to ~18.6% (from ~16.7% QoQ) but operating margin eased to ~26.5% from 27.7% in Q4 — a mild compression consistent with newly commissioned units (Panchkula, 350 beds, live Apr-10; Rudrapur, 330 beds, launched Aug-2) absorbing ramp-up costs before hitting steady-state utilisation. This directly tests management's prior-call guidance that new hospitals would ramp "without diluting margins"; the YoY margin picture holds, but the sequential OPM dip is the line to watch. There is no published street consensus for this recently-listed name — coverage is thin — though the stock rose ~5% into the print on positioning.
The stock went into the print at ₹295.8, up 0.3% over the past month of trading.
Management guides for significant bed capacity growth to 5,460 by March 2028, funded by strong internal cash flows with a total capex of approximately INR 500 crores. They anticipate a 5-6% net revenue benefit from the CGHS rate hike in FY'27 and expect new hospitals to ramp up without diluting overall margins. The com
— This quarter: met
The quarter's board actions reinforce the expansion thesis management has been selling. Alongside results, the board approved the all-cash ₹107 Cr acquisition of Mehar Hospital, Zirakpur (150+ beds), densifying the Tricity cluster; this follows the ₹177 Cr Medicity/Rudrapur deal and Panchkula commissioning. Management now guides total capacity to ~5,800 beds by March 2028 — an upward revision from the ~5,460 flagged on the Q4 call — after adding ~1,500 beds (~46%) in twelve months, framing the print as "pace and prudence" with acquisitions structured to be earnings-accretive. Funding leans on internal accruals plus unutilised IPO proceeds (₹648 Cr pending as on June-30). The near-term question is whether the CGHS-linked 5-6% revenue tailwind management guided for FY27 and improving utilisation at the new units lift OPM back toward 27-28% as the added beds mature.
W1
Operating margin trajectory: whether OPM recovers from ~26.5% toward the 27-28% range as Panchkula/Rudrapur mature — management guided new hospitals ramp 'without diluting margins'
W2
Effective tax rate normalisation: Q1 PAT was lifted by a ₹9.3 Cr deferred-tax benefit (15.7% effective rate); reversion would compress reported PAT growth even if PBT holds
W3
CGHS rate-hike realisation: management guided a 5-6% net revenue benefit in FY27 — watch topline for evidence it is flowing through
Clean digital PDF; statement in ₹ millions (÷10 to Cr). No exceptional items. Consolidated PAT ₹88.59 Cr = owners ₹82.51 Cr + non-controlling interest ₹6.09 Cr; EPS ₹2.05 is on owners' share. QoQ PAT flattered by tax: effective rate 15.7% (₹9.3 Cr deferred-tax benefit) vs 25.7% in Q4; PBT near-flat QoQ (₹105.08 vs ₹103.39 Cr). YoY column present in PDF though absent in DB.
Steady execution amid capacity dilution; long-term roadmap raised
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 delivered as guided (₹475.7 Cr rev, ₹88.6 Cr PAT). No prior FY'27 guidance to assess; capacity (5,460→5,740) and CGHS (5-6%→7-7.5%) targets raised.
Cautiously Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong long-term capacity and payor-mix roadmap (5,740 beds by FY'28, 70:30 split, 7-7.5% CGHS benefit) with quantified targets and structural tailwinds. But near-term execution risk: 56% occupancy, three major acquisitions (Rudrapur ₹177 Cr, Zirakpur ₹107 Cr, Narela) all in ramp phase with aggressive unproven revenue/EBITDA targets. CGHS benefit claimed to flow to CAPEX, not EBITDA; wait for Q2-Q4 clarity.
₹475.7 Cr
Revenue · +null% YoY₹88.6 Cr
Reported PAT · +null% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Q1 revenue ₹476 Cr, PAT ₹89 Cr at 18.6% margin
METDelivered ₹475.7 Cr revenue, ₹88.6 Cr PAT at 18.3% margin
EBITDA margin 26.5%, improved vs Q1 FY'26's 26.3%
METDelivered OPM 26.5%, consistent with call
IPD +16% YoY, OPD +17% YoY, ARPOB +12% YoY
METManagement cited 26,304 IPDs, 2,23,446 OPDs, ₹30,444 ARPOB; QoQ growth consistent with delivered +3.3% revenue, +15.4% PAT
Occupancy fell to 56% due to 960 new beds added; FY'27 to moderate from FY'26's 64%
METDown from 68% a year ago; new capacity (Bhatinda 250, Agra 360, Panchkula 350) ramping as planned
CGHS rate hike (12-15%, Oct 2025) will yield 7-7.5% net benefit; partial impact Q1, full from Q2
UnverifiedNo CGHS benefit visible in Q1 margins (EBITDA flat vs prior); claim deferred to Q2-Q4 rollout
Earnings quality
What changed since the last call
Capacity guidance raised
UpgradePrior 5,460 beds by Mar 2028 → now 5,740 beds by FY'28 (280-bed upgrade). Funded by internal accruals + IPO proceeds; no fresh debt.
CGHS benefit upgraded
UpgradePrior guidance 5-6% net revenue benefit → now 7-7.5% (Oct 2025 rate hike was 12-15%; 70% CGHS patient base). But caveat: mostly flows to CAPEX.
FY'27 financial targets set
NewRevenue ₹2,080 Cr (24% YoY), EBITDA ₹530 Cr (25% YoY), PAT ₹360 Cr (32% YoY); EBITDA margin 26-27%, PAT margin 17-18%. First explicit annual guidance.
Occupancy headwind acknowledged
Neutral56% in Q1 (down from 68% a year ago). FY'27 guided at ~64% (moderation from FY'26's actual 64%). New capacity (960 beds past 12mo, 1,490 in CY2026) to drive multi-quarter occupancy drag before recovery.
The Q&A
Analysts pressed hard on EBITDA losses at Greenfield units, CAPEX per bed economics, and execution bandwidth for multiple acquisitions. Management held firm, cited Mohali success (52 Lakh→₹23 Cr revenue, 12-13% Y1 margin→18-19% now) and claimed second-line training pipeline. Some deflection on granular occupancy/ARPOB splits by asset class; did not quantify attrition at HoD level.
FY'27 revenue and margin guidance — Anshul Agrawal, Emkay Global Financial Services
AnsweredFY'27 top line ₹2,080 Cr (24% YoY), EBITDA ₹530 Cr (25% YoY), PAT ₹360 Cr (32% YoY). No EBITDA loss expected at new units; Mohali example shows Y1 at 12-13%, now 18-19%, targeting 26%.
Greenfield unit EBITDA trajectory — Anshul Agrawal, Emkay Global Financial Services
AnsweredNo losses expected. New units (Agra, Panchkula) generating 7-9 months revenue in FY'27; expected EBITDA-positive at 10-12% margin Y1. Mature hospitals (Gurgaon, Mohali, Ambala) growing 18-20%; blended 26-27% EBITDA margin held for FY'27.
CGHS rate benefit quantification — Kashish Thakur, Elara Capital; Sagar Tanna, Alchemie Ventures
PartialRate hike was Oct 2025; 70% of patients on CGHS → ~7-7.5% net benefit. Started flowing partially in Q1; full impact Q2-Q4. But benefit will be utilised for CAPEX/equipment upgrades, not directly to PAT. EBITDA margin will be maintained 26-27%, PAT 17-18%.
Acquisition integration bandwidth — Nirali Shah, Ashika Investment Managers
AnsweredContinuous training of second-line management in existing hospitals; all top management trained 6-8 months before new facility launch. Rudrapur, Agra, Panchkula management already embedded in existing units. Process is continuous; no foreseen bandwidth constraint.
Bed capacity guidance change — Shubham Padhiar, Chhattisgarh Investments
AnsweredGuidance was conservative, consistent. Q1 guidance: 3,960 beds (with Panchkula 350). Q2: 4,290 (Rudrapur 330 commissioned 2 Aug). Q3: 4,740 (Palam Vihar 100, Zirakpur 150). FY'28: 5,740 (add 1,000 beds). Kanpur remains optional; these are identified, visible, unequivocally communicated assets.
Case mix and specialty strategy — Sumit Gupta, Antique Stock Broking
PartialOrganic growth; hard to project exact %age. Oncology 9-10%, Cardiology 12%, Joint replacement 9.5%, Neurology 14.5%, Urology 11%, Gastro 7%. New acquisitions (Rudrapur, Zirakpur) will have similar high-end focus. No fixed target, driven by market demand.
Doctor retention in Tier-2/3 cities — Chetan Shah, Jeet Capital; Sumit Gupta, Antique Stock Broking
AnsweredAttrition at consultant level is lowest in industry; doctors treated as partners (accountable only for patient satisfaction, clinical outcomes). Remuneration via monthly performance bonus, ESOP. Example: Bhatinda, Rudrapur docs returning to hometowns for world-class facilities. No visiting consultant model; all 100% dedicated to Park. No franchisee partnerships planned.
Payer mix transition to 70:30 — Ronak Agarwal, ithought PMS
AnsweredShift to 70:30 expected in next 12-15 months. Cash/TPA patients attracted by affordable super-specialty offering. ARPOB currently growing 10-12% (vs 3-5% historical); trend to continue 10-12% for 2 years due to case mix, national inflation, payor mix.
OPD strategy and revenue model — Akshay Thakur, Helios Capital
AnsweredOPD is footfall generator, not revenue target. Free/subsidized OPD for affordability mission; 20-25 camps/month per unit (CSR). Gazetted holidays OPDs free. High consultation fees (₹3-5K super-specialist) become deterrent for lower-income patients. OPD drives conversion when patients see affordable treatment availability.
Neurology speciality concentration — Akshay Thakur, Helios Capital
AnsweredDomain-centric; Highway location (Delhi-Chandigarh GT Road, Jaipur-Delhi Expressway) attracts trauma/accident cases. High neurological involvement in critical cases. Not a deliberate focus; organic outcome of geography.
Guidance
FY'27: ₹2,080 Cr (24% YoY growth)
MediumQ1 run-rate ₹476 Cr × 4 = ₹1,904 Cr baseline. FY'27 adds Rudrapur Y1 (₹100 Cr), Narela ramp, Zirakpur partial, plus mature hospital 18-20% growth. Plausible but dependent on Rudrapur/Narela delivery.
FY'27 EBITDA margin: 26-27% (vs Q1 actual 26.5%)
MediumHeld despite 1,490 new beds (950 occupied at low occupancy, dragging average). Blended assumption: above-60% occupancy units at 30-31% EBITDA, sub-60% at 15-20%.
FY'27 PAT margin: 17-18% (vs Q1 actual 18.3%)
MediumLower interest expense from debt reduction (+220 bps vs Q1 FY'26) should persist. CGHS benefit will flow to CAPEX, not margin. Slight pressure expected.
FY'27-FY'28 total capex: ₹767 Cr for 2,130 beds = ₹36 Lakh per bed
HighIncludes acquisitions (Rudrapur ₹177 Cr, Zirakpur ₹107 Cr) + Greenfield (Panchkula, Narela, Palam Vihar). Lowest in listed peers at ₹37 Lakh per bed (Q1).
Risks the call surfaced
Acquisition integration execution
HighRudrapur ₹100 Cr Y1 target (was ₹55-56 Cr annually before acquisition at 200 beds, now 330). Narela (200-bed insolvent asset) and Zirakpur (₹70-75 Cr FY28 guidance) unproven. Three simultaneous integrations in 12-18 months.
Occupancy dilution
HighQ1 occupancy 56% (down from 68% a year ago). 1,490 beds added in CY2026 (46% of existing base). If occupancy remains <60% for 4+ quarters, blended margin dilution likely.
CGHS benefit monetization
MediumOct 2025 CGHS rate hike 12-15%; Park conservatively guides 7-7.5% net benefit (70% patient base on CGHS). But management explicitly stated benefit will flow to equipment/capex upgrades, not EBITDA/PAT.
Competitive cost pressure (oncology)
MediumAnalyst noted one peer facing impact in onco segment from CGHS rate revision. Park claims strong vendor supply chain and negotiating power, but no hard data. Onco is 9-10% of revenue; margin hit here would cascade.
Doctor retention in tier-2/3
MediumExpansion into Bhatinda, Rudrapur, Zirakpur depends on attracting super-specialists. Management cites hometown appeal and better facilities, but no hard attrition metrics. Salary inflation in metros may pressure tier-2 talent pool.
Regulatory/payor mix uncertainty
Low77% revenue from government schemes. Policy changes (caps, denial rates) could compress revenue. Shift to 70:30 mitigates exposure but is multi-quarter effort.
Management
Score 7/10. Clear, detailed, specific on numbers and roadmaps. Acknowledged occupancy dilution and capacity headwinds. Hedged on CGHS benefit flow-through. Some deflection on granular metrics (attrition rate, exact occupancy recovery curve). Strong track record: FY'26 described as 'strongest year in company's history.' Delivered Q1 as guided (₹476 Cr rev, ₹126 Cr EBITDA, ₹89 Cr PAT). Agra/Panchkula ramping as planned. But acquisitions (Rudrapur, Narela, Zirakpur) unproven; need 12-18 months to assess.
1 · Q2 FY27 (Aug-Sep 2026)
Full CGHS rate benefit begins to flow (partial in Q1); occupancy guidance for FY'27 reset based on H1 ramp trajectory
2 · Nov-Dec 2026
Rudrapur, Narela, Zirakpur commissioning (450 beds total); initial revenue ramp begins
3 · FY28 guidance (Feb 2027)
Management updates bed capacity and revenue targets for FY28 based on 2000+ bed ramp; payor mix progress to 70:30 disclosed
CGHS benefit claimed to flow to CAPEX, not EBITDA; wait for Q2-Q4 clarity.